✦ LIBER ✦

The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study

✍ Scribed by Heiberg, Marte Schrumpf ;Koldingsnes, Wenche ;Mikkelsen, Knut ;Rødevand, Erik ;Kaufmann, Cecilie ;Mowinckel, Petter ;Kvien, Tore K.

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 166 KB
Volume: 59
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.23333

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The comparative effectiveness of tumor n

The comparative effectiveness of tumor necrosis factor–blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: A six-month, longitudinal, observational, multicenter study

✍ Marte S. Heiberg; Bjørn-Yngvar Nordvåg; Knut Mikkelsen; Erik Rødevand; Cecilie K 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

Outcomes after switching from one anti–t

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

✍ Kimme L. Hyrich; Mark Lunt; Kath D. Watson; Deborah P. M. Symmons; Alan J. Silma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti‐TNF agent, although the benefits of switching are unknown. The pres

Single-center series and systematic revi

Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor α therapy: Is there a need for more comprehensive screening procedures?

✍ Nannini, Carlotta ;Cantini, Fabrizio ;Niccoli, Laura ;CassarÀ, Emanuele ;Salvara 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

Reduction in the incidence of myocardial

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

✍ W. G. Dixon; K. D. Watson; M. Lunt; K. L. Hyrich; A. J. Silman; D. P. M. Symmons 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Erratum: Golimumab, a human anti-tumor n

Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB